Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma

Akinao Okamoto, Masamitsu Yanada, Hiroki Miura, Yoko Inaguma, Masutaka Tokuda, Satoko Morishima, Tadaharu Kanie, Yukiya Yamamoto, Shuichi Mizuta, Yoshiki Akatsuka, Tetsushi Yoshikawa, Yoshikazu Mizoguchi, Shigeo Nakamura, Masataka Okamoto, Nobuhiko Emi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

It is still a matter of debate whether detection of Epstein-Barr virus (EBV) DNA in pretreatment serum has clinical implications for diffuse large B-cell lymphoma. For this study, we measured EBV DNA load in pretreatment serum from 127 diffuse large B-cell lymphoma patients without any underlying immunodeficiency to evaluate its effects on clinical manifestations and prognosis. Anthracycline-based chemotherapy in combination with rituximab was given as initial therapy for 119 patients (94%). Epstein-Barr virus DNA was detected in 15 patients (12%), who were older (P = 0.005) and tended to be at a more advanced disease stage (P = 0.053). They showed significantly worse progression-free survival (PFS) and overall survival (OS) than other patients (P < 0.001 each). This effect remained significant (P = 0.004 and P = 0.027, respectively) after adjustment for age, lactate dehydrogenase, performance status, stage, and extranodal sites. The status of EBV-encoded small RNA in situ hybridization was known for 123 patients; 6 of 8 positive patients (75%) and 9 of 115 negative patients (8%) had detectable EBV DNA in pretreatment serum. While patients positive for EBV-encoded small RNA had significantly worse PFS and OS than negative patients (P = 0.001 and P = 0.029, respectively), EBV DNA detection in pretreatment serum was associated with poorer PFS and OS even for the 115 patients negative for EBV-encoded small RNA (P < 0.001 each). These findings suggest that EBV DNA detection in pretreatment serum may have an adverse prognostic impact for patients with diffuse large B-cell lymphoma. For this study, we measured Epstein-Barr virus DNA load in pretreatment serum from 127 diffuse large B-cell lymphoma patients to evaluate its effects on clinical manifestations and prognosis. Our findings show that Epstein-Barr virus DNA detection in pretreatment serum may have an adverse prognostic impact.

Original languageEnglish
Pages (from-to)1576-1581
Number of pages6
JournalCancer Science
Volume106
Issue number11
DOIs
Publication statusPublished - 01-11-2015

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Human Herpesvirus 4
DNA
Serum
Disease-Free Survival
RNA
Survival
Anthracyclines
Combination Drug Therapy
L-Lactate Dehydrogenase
In Situ Hybridization

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Okamoto, Akinao ; Yanada, Masamitsu ; Miura, Hiroki ; Inaguma, Yoko ; Tokuda, Masutaka ; Morishima, Satoko ; Kanie, Tadaharu ; Yamamoto, Yukiya ; Mizuta, Shuichi ; Akatsuka, Yoshiki ; Yoshikawa, Tetsushi ; Mizoguchi, Yoshikazu ; Nakamura, Shigeo ; Okamoto, Masataka ; Emi, Nobuhiko. / Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma. In: Cancer Science. 2015 ; Vol. 106, No. 11. pp. 1576-1581.
@article{5e0dfb5ad35542849e2d98b84cb82010,
title = "Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma",
abstract = "It is still a matter of debate whether detection of Epstein-Barr virus (EBV) DNA in pretreatment serum has clinical implications for diffuse large B-cell lymphoma. For this study, we measured EBV DNA load in pretreatment serum from 127 diffuse large B-cell lymphoma patients without any underlying immunodeficiency to evaluate its effects on clinical manifestations and prognosis. Anthracycline-based chemotherapy in combination with rituximab was given as initial therapy for 119 patients (94{\%}). Epstein-Barr virus DNA was detected in 15 patients (12{\%}), who were older (P = 0.005) and tended to be at a more advanced disease stage (P = 0.053). They showed significantly worse progression-free survival (PFS) and overall survival (OS) than other patients (P < 0.001 each). This effect remained significant (P = 0.004 and P = 0.027, respectively) after adjustment for age, lactate dehydrogenase, performance status, stage, and extranodal sites. The status of EBV-encoded small RNA in situ hybridization was known for 123 patients; 6 of 8 positive patients (75{\%}) and 9 of 115 negative patients (8{\%}) had detectable EBV DNA in pretreatment serum. While patients positive for EBV-encoded small RNA had significantly worse PFS and OS than negative patients (P = 0.001 and P = 0.029, respectively), EBV DNA detection in pretreatment serum was associated with poorer PFS and OS even for the 115 patients negative for EBV-encoded small RNA (P < 0.001 each). These findings suggest that EBV DNA detection in pretreatment serum may have an adverse prognostic impact for patients with diffuse large B-cell lymphoma. For this study, we measured Epstein-Barr virus DNA load in pretreatment serum from 127 diffuse large B-cell lymphoma patients to evaluate its effects on clinical manifestations and prognosis. Our findings show that Epstein-Barr virus DNA detection in pretreatment serum may have an adverse prognostic impact.",
author = "Akinao Okamoto and Masamitsu Yanada and Hiroki Miura and Yoko Inaguma and Masutaka Tokuda and Satoko Morishima and Tadaharu Kanie and Yukiya Yamamoto and Shuichi Mizuta and Yoshiki Akatsuka and Tetsushi Yoshikawa and Yoshikazu Mizoguchi and Shigeo Nakamura and Masataka Okamoto and Nobuhiko Emi",
year = "2015",
month = "11",
day = "1",
doi = "10.1111/cas.12812",
language = "English",
volume = "106",
pages = "1576--1581",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

Okamoto, A, Yanada, M, Miura, H, Inaguma, Y, Tokuda, M, Morishima, S, Kanie, T, Yamamoto, Y, Mizuta, S, Akatsuka, Y, Yoshikawa, T, Mizoguchi, Y, Nakamura, S, Okamoto, M & Emi, N 2015, 'Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma', Cancer Science, vol. 106, no. 11, pp. 1576-1581. https://doi.org/10.1111/cas.12812

Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma. / Okamoto, Akinao; Yanada, Masamitsu; Miura, Hiroki; Inaguma, Yoko; Tokuda, Masutaka; Morishima, Satoko; Kanie, Tadaharu; Yamamoto, Yukiya; Mizuta, Shuichi; Akatsuka, Yoshiki; Yoshikawa, Tetsushi; Mizoguchi, Yoshikazu; Nakamura, Shigeo; Okamoto, Masataka; Emi, Nobuhiko.

In: Cancer Science, Vol. 106, No. 11, 01.11.2015, p. 1576-1581.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma

AU - Okamoto, Akinao

AU - Yanada, Masamitsu

AU - Miura, Hiroki

AU - Inaguma, Yoko

AU - Tokuda, Masutaka

AU - Morishima, Satoko

AU - Kanie, Tadaharu

AU - Yamamoto, Yukiya

AU - Mizuta, Shuichi

AU - Akatsuka, Yoshiki

AU - Yoshikawa, Tetsushi

AU - Mizoguchi, Yoshikazu

AU - Nakamura, Shigeo

AU - Okamoto, Masataka

AU - Emi, Nobuhiko

PY - 2015/11/1

Y1 - 2015/11/1

N2 - It is still a matter of debate whether detection of Epstein-Barr virus (EBV) DNA in pretreatment serum has clinical implications for diffuse large B-cell lymphoma. For this study, we measured EBV DNA load in pretreatment serum from 127 diffuse large B-cell lymphoma patients without any underlying immunodeficiency to evaluate its effects on clinical manifestations and prognosis. Anthracycline-based chemotherapy in combination with rituximab was given as initial therapy for 119 patients (94%). Epstein-Barr virus DNA was detected in 15 patients (12%), who were older (P = 0.005) and tended to be at a more advanced disease stage (P = 0.053). They showed significantly worse progression-free survival (PFS) and overall survival (OS) than other patients (P < 0.001 each). This effect remained significant (P = 0.004 and P = 0.027, respectively) after adjustment for age, lactate dehydrogenase, performance status, stage, and extranodal sites. The status of EBV-encoded small RNA in situ hybridization was known for 123 patients; 6 of 8 positive patients (75%) and 9 of 115 negative patients (8%) had detectable EBV DNA in pretreatment serum. While patients positive for EBV-encoded small RNA had significantly worse PFS and OS than negative patients (P = 0.001 and P = 0.029, respectively), EBV DNA detection in pretreatment serum was associated with poorer PFS and OS even for the 115 patients negative for EBV-encoded small RNA (P < 0.001 each). These findings suggest that EBV DNA detection in pretreatment serum may have an adverse prognostic impact for patients with diffuse large B-cell lymphoma. For this study, we measured Epstein-Barr virus DNA load in pretreatment serum from 127 diffuse large B-cell lymphoma patients to evaluate its effects on clinical manifestations and prognosis. Our findings show that Epstein-Barr virus DNA detection in pretreatment serum may have an adverse prognostic impact.

AB - It is still a matter of debate whether detection of Epstein-Barr virus (EBV) DNA in pretreatment serum has clinical implications for diffuse large B-cell lymphoma. For this study, we measured EBV DNA load in pretreatment serum from 127 diffuse large B-cell lymphoma patients without any underlying immunodeficiency to evaluate its effects on clinical manifestations and prognosis. Anthracycline-based chemotherapy in combination with rituximab was given as initial therapy for 119 patients (94%). Epstein-Barr virus DNA was detected in 15 patients (12%), who were older (P = 0.005) and tended to be at a more advanced disease stage (P = 0.053). They showed significantly worse progression-free survival (PFS) and overall survival (OS) than other patients (P < 0.001 each). This effect remained significant (P = 0.004 and P = 0.027, respectively) after adjustment for age, lactate dehydrogenase, performance status, stage, and extranodal sites. The status of EBV-encoded small RNA in situ hybridization was known for 123 patients; 6 of 8 positive patients (75%) and 9 of 115 negative patients (8%) had detectable EBV DNA in pretreatment serum. While patients positive for EBV-encoded small RNA had significantly worse PFS and OS than negative patients (P = 0.001 and P = 0.029, respectively), EBV DNA detection in pretreatment serum was associated with poorer PFS and OS even for the 115 patients negative for EBV-encoded small RNA (P < 0.001 each). These findings suggest that EBV DNA detection in pretreatment serum may have an adverse prognostic impact for patients with diffuse large B-cell lymphoma. For this study, we measured Epstein-Barr virus DNA load in pretreatment serum from 127 diffuse large B-cell lymphoma patients to evaluate its effects on clinical manifestations and prognosis. Our findings show that Epstein-Barr virus DNA detection in pretreatment serum may have an adverse prognostic impact.

UR - http://www.scopus.com/inward/record.url?scp=84983126707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983126707&partnerID=8YFLogxK

U2 - 10.1111/cas.12812

DO - 10.1111/cas.12812

M3 - Article

VL - 106

SP - 1576

EP - 1581

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -